@article{oai:repo.qst.go.jp:00046881,
 author = {Barron Anna and M, Garcia-Segura Luis and Caruso, Donatella and Jayaraman, Anusha and Lee, Joo-Won and C, Melcangi Roberto and J, Pike Christian and Ｂａｒｒｏｎ Ａｎｎａ},
 issue = {20},
 journal = {The Journal of neuroscience : the official journal of the Society for Neuroscience},
 month = {May},
 note = {Ligands of the translocator protein (TSPO) elicit pleiotropic neuroprotective effects that represent emerging treatment strategies for several neurodegenerative conditions. To investigate the potential of TSPO as a therapeutic target for Alzheimer's disease (AD), the current study assessed the effects of the TSPO ligand Ro5-4864 on the development of neuropathology in 3xTgAD mice. The effects of the TSPO ligand on neurosteroidogenesis and AD-related neuropathology, including β-amyloid accumulation, gliosis, and behavioral impairment, were examined under both early intervention (7-month-old young-adult male mice with low pathology) and treatment (24-month-old, aged male mice with advanced neuropathology) conditions. Ro5-4864 treatment not only effectively attenuated development of neuropathology and behavioral impairment in young-adult mice but also reversed these indices in aged 3xTgAD mice. Reduced levels of soluble β-amyloid were also observed by the combination of TSPO ligands Ro5-4864 and PK11195 in nontransgenic mice. These findings suggest that TSPO is a promising target for the development of pleiotropic treatment strategies for the management of AD.},
 pages = {8891--8897},
 title = {Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease.},
 volume = {33},
 year = {2013}
}